HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

'For When You Forget Your Jungle Formula' – Perrigo Launches UK Bite & Sting Range

Executive Summary

Perrigo UK & Ireland offers relief for UK consumers on holiday without their Jungle Formula.

You may also be interested in...



Perrigo Gives UK Dieters A Boost With XLS-Medical

Perrigo launches new XLS-Medical Ultra 5 slimming aid just in time for the UK government's new weight-loss drive in response to the COVID-19 pandemic.

Perrigo Strengthens In Europe With Sanofi Skin-Care Brands

Perrigo is investing to grow its reinvigorated International consumer health business by acquiring three OTC skin-care brands from Sanofi. 

Safety First For Perrigo In CBD Market; ‘Long-Term’ Play Starts With Clinical Trials

Perrigo’s clinical trials on CBD likely will take years before resulting products help bring order to the market. During earnings presentation, CEO Murray Kessler says the trials aren’t intended to establish claims for CBD but are more a long-term effort to provide data to FDA.

Related Content

Topics

UsernamePublicRestriction

Register

RS150527

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel